Dongsung Pharmaceutical Appoints Experienced Pharma Executive Choi Yong-seok as New CEO


  • Dongsung Pharmaceutical appointed Choi Yong-seok as its new CEO effective April 14, 2026, subject to court approval.
  • The new CEO has extensive experience at major pharmaceutical companies including AstraZeneca, Takeda, and Hanmi Pharmaceutical.
  • Along with the CEO appointment, four outside directors and two non-executive directors were newly appointed to strengthen governance and expertise.
  • [AI Summary]The appointment of a new CEO and board members enhances management stability and expertise but does not directly impact short-term share value, warranting a neutral assessment.

KOSPI Filing Information


  • Filing: Change Of Representative Director (Representative Executive Officer) (Notice Disclosure)
  • Company: Dongsung Pharmaceutical (002210)
  • Submission: Dongsung Pharmaceutical Co., Ltd.
  • Receipt: 04-15-2026
  • Under KRX KOSPI Market Division